Aptar Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aptar Pharma

Pharmaceutical Technology Europe

Company name: Aptar Pharma
Address: 36-38 rue de la Princesse, 78430 Louveciennes, France
Telephone: +33 1 39 17 20 20
Fax: +33 1 39 58 12 98
E-mail: guillaume.le_brun@aptar.com
Website: www.aptar.com
No. of employees: 2 280
Date founded: 1947

Aptar Pharma is the segment within the Aptargroup family dedicated to the pharmaceutical market. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world.

Aptar Pharma is market driven with a strong focus on specific therapeutic areas such as as allergic rhinitis, asthma, COPD, pain management, hormone therapies, mucosal vaccines as well as cough & cold ailments.

The Aptar Pharma Prescription Division specializes in novel drug delivery solutions - i.e. pMDIs, DPIs, Spray Pumps and UnitDoses - specific to physician-prescribed medicines while the Consumer Health Care Division offers dispensing solutions adapted to over-the-counter medications.

Our manufacturing facilities are located in Buenos Aires (Argentina), Congers (NY, U.S.A.), Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France) and Suzhou (near Shanghai, R.O.C.).

Approximately 6% of Aptar Pharma’s annual turnover is dedicated to research, development and industrialization of novel products. Our R&D and Marketing staff work closely together in a global market-focused team of 200 people dedicated to satisfying customer needs.

Aptar Pharma R&D centres of excellence are located in Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France).

www.aptar.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology Europe,
Click here